MCL1 and cancer: An efficacious strategy to overcome the drawbacks or enhance the therapeutic effect of ABT‐737 is to combine anticancer compounds that obtained activity to abrogate Mcl‐1 protein level, and these combinations have been reported to achieve synergistic effect in various cancer cell lines 23, 24.